| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Kenneth Rockwood | Q57982861 |
| P2093 | author name string | Xiaowei Song | |
| Robert Bartha | |||
| Ningnannan Zhang | |||
| Yunting Zhang | |||
| Steven Beyea | |||
| Ryan D'Arcy | |||
| P2860 | cites work | 1 H MR Spectroscopy of the Brain: Absolute Quantification of Metabolites 1 | Q22065378 |
| Alzheimer's Disease | Q22248111 | ||
| Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 | ||
| The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29547554 | ||
| Increased glucose concentration in the hippocampus in early Alzheimer's disease following oral glucose ingestion | Q30440916 | ||
| In vivo 1H NMR spectroscopy of the human brain at 9.4 T: initial results | Q30474364 | ||
| Proton MRS in mild cognitive impairment | Q30606675 | ||
| Magnetic resonance spectroscopy in Alzheimer's disease | Q30630699 | ||
| Role of Increased Cerebral myo‐Inositol in the Dementia of Down Syndrome | Q45307554 | ||
| An MRI brain atrophy and lesion index to assess the progression of structural changes in Alzheimer's disease, mild cognitive impairment, and normal aging: a follow-up study. | Q45715352 | ||
| Comparison of machine learning techniques with classical statistical models in predicting health outcomes. | Q45966672 | ||
| A multicenter (1)H-MRS study of the medial temporal lobe in AD and MCI. | Q46006742 | ||
| Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy. | Q46019129 | ||
| Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy | Q46412580 | ||
| Absolute quantification in proton magnetic resonance spectroscopy is superior to relative ratio to discriminate Alzheimer's disease from Binswanger's disease | Q46490260 | ||
| Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy | Q46528864 | ||
| Choline ingestion increases the resonance of choline-containing compounds in human brain: an in vivo proton magnetic resonance study | Q42278805 | ||
| Combining MRI and MRS to distinguish between Alzheimer's disease and healthy controls | Q42905311 | ||
| Absolute Quantification in Proton Magnetic Resonance Spectroscopy Is Useful to Differentiate Amnesic Mild Cognitive Impairment from Alzheimer’s Disease and Healthy Aging | Q42944825 | ||
| Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy | Q43252674 | ||
| Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease | Q43260715 | ||
| Dynamics of brain structure and cognitive function in the Alzheimer's disease neuroimaging initiative | Q43683015 | ||
| In vivo 1H NMR spectroscopy of the human brain at 7 T. | Q43732942 | ||
| Biexponential transverse relaxation (T(2)) of the proton MRS creatine resonance in human brain | Q43866051 | ||
| Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease | Q43941006 | ||
| Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease | Q44147111 | ||
| Impaired visual recognition memory in amnestic mild cognitive impairment is associated with mesiotemporal metabolic changes on magnetic resonance spectroscopic imaging | Q44266860 | ||
| Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T | Q44441773 | ||
| Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy | Q44643487 | ||
| A comparative study of myo-inositol quantification using LCmodel at 1.5 T and 3.0 T with 3 D 1H proton spectroscopic imaging of the human brain | Q44878088 | ||
| Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease | Q44940013 | ||
| High cerebral scyllo-inositol: a new marker of brain metabolism disturbances induced by chronic alcoholism | Q45039345 | ||
| Proton spectroscopy in Alzheimer's disease and cognitive impairment no dementia: a community-based study | Q46622896 | ||
| High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. | Q46770368 | ||
| Focally elevated creatine detected in amyloid precursor protein (APP) transgenic mice and Alzheimer disease brain tissue | Q46788465 | ||
| Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia | Q46829361 | ||
| Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. | Q46891214 | ||
| Magnetic resonance spectroscopic study of Alzheimer's disease and frontotemporal dementia/Pick complex. | Q46973579 | ||
| A multi-metabolite analysis of serum by 1H NMR spectroscopy: early systemic signs of Alzheimer's disease | Q47401613 | ||
| A localized double-quantum filter for in vivo detection of taurine | Q48124229 | ||
| Factors affecting the quantification of short echo in-vivo 1H MR spectra: prior knowledge, peak elimination, and filtering | Q48152149 | ||
| Identification of Scyllo-inositol in proton NMR spectra of human brain in vivo. | Q48368950 | ||
| Spectral editing technique for the in vitro and in vivo detection of taurine | Q48434937 | ||
| Robust fully automated shimming of the human brain for high-field 1H spectroscopic imaging | Q48500479 | ||
| On areas of transition between entorhinal allocortex and temporal isocortex in the human brain. Normal morphology and lamina-specific pathology in Alzheimer's disease | Q48538921 | ||
| Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study | Q48577021 | ||
| Hippocampal metabolites and memory performances in patients with amnestic mild cognitive impairment and Alzheimer's disease | Q48628708 | ||
| Longitudinal magnetic resonance spectroscopy as marker of cognitive deterioration in mild cognitive impairment | Q48665796 | ||
| The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. | Q48691421 | ||
| Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. | Q48732771 | ||
| On the identification of cerebral metabolites in localized1H NMR spectra of human brainIn vivo | Q48763413 | ||
| Automatic quantitation of localized in vivo 1H spectra with LCModel | Q48842365 | ||
| Single-voxel proton MRS of the human brain at 1.5T and 3.0T. | Q48899796 | ||
| Improved quantification of in vivo 1H NMR spectra by optimization of signal acquisition and processing and by incorporation of prior knowledge into the spectral fitting | Q48930170 | ||
| Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias | Q49039021 | ||
| Quantitative proton MR spectroscopic imaging of the human brain | Q49094238 | ||
| Evaluation of common structural brain changes in aging and Alzheimer disease with the use of an MRI-based brain atrophy and lesion index: a comparison between T1WI and T2WI at 1.5T and 3T. | Q49100694 | ||
| Using proton magnetic resonance spectroscopy to identify mild cognitive impairment | Q49162235 | ||
| Longitudinal study of amnesic patients at high risk for Alzheimer's disease: clinical, neuropsychological and magnetic resonance spectroscopy features. | Q51108602 | ||
| Brain oxidative stress: detection and mapping of anti-oxidant marker 'Glutathione' in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy. | Q51173688 | ||
| Executive function is associated with brain proton magnetic resonance spectroscopy in amnestic mild cognitive impairment. | Q51972858 | ||
| Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. | Q52001947 | ||
| Morphological changes in the human cerebral cortex in dementia | Q53182084 | ||
| Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity. | Q53234286 | ||
| Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. | Q53236578 | ||
| 1-H MRS changes in dorsolateral prefrontal cortex after donepezil treatment in patients with mild to moderate Alzheimer's disease. | Q53319688 | ||
| Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. | Q53394958 | ||
| 1H NMR chemical shift selective (CHESS) imaging | Q57530731 | ||
| Comparison of the quantification precision of human short echo time1H spectroscopy at 1.5 and 4.0 Tesla | Q63894296 | ||
| Measurement of the magnetic susceptibility effect in high-field NMR imaging | Q68335776 | ||
| Estimation of metabolite concentrations from localized in vivo proton NMR spectra | Q72319396 | ||
| In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard | Q80406112 | ||
| Neurochemical alterations of the entorhinal cortex in amnestic mild cognitive impairment (aMCI): a three-year follow-up study | Q84141182 | ||
| Magnetic resonance spectroscopy in AD. | Q30640894 | ||
| Magnetic resonance spectroscopy in common dementias | Q30660402 | ||
| High-field magnetic resonance techniques for brain research | Q30884505 | ||
| High-field proton MRS of human brain | Q30886341 | ||
| Proton magnetic resonance spectroscopy: clinical applications in patients with brain lesions | Q30909042 | ||
| 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. | Q30945792 | ||
| A review of 1H MR spectroscopy findings in Alzheimer's disease | Q31030920 | ||
| A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline | Q31033036 | ||
| N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain | Q31034516 | ||
| Differential aging of the brain: patterns, cognitive correlates and modifiers | Q31055402 | ||
| The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. | Q31090249 | ||
| Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements | Q31159878 | ||
| Magnetic resonance spectroscopy of neurotransmitters in human brain. | Q33187959 | ||
| Short echo time 1H-MRSI of the human brain at 3T with minimal chemical shift displacement errors using adiabatic refocusing pulses | Q33304310 | ||
| Proton magnetic resonance spectroscopy in dementias and mild cognitive impairment | Q33462288 | ||
| Methodology of H NMR Spectroscopy of the Human Brain at Very High Magnetic Fields | Q33533781 | ||
| Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS | Q33745448 | ||
| In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. | Q33745500 | ||
| MR spectroscopy and spectroscopic imaging of the brain | Q33807151 | ||
| Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans | Q33842520 | ||
| Metabolism and functions of glutathione in brain. | Q33908238 | ||
| Regional neurochemical profiles in the human brain measured by ¹H MRS at 7 T using local B₁ shimming. | Q33964122 | ||
| N-acetylaspartate, choline, myoinositol, glutamine and glutamate (glx) concentration changes in proton MR spectroscopy (1H MRS) in patients with mild cognitive impairment (MCI). | Q34029600 | ||
| In vivo detection of serine in the human brain by proton magnetic resonance spectroscopy (1H-MRS) at 7 Tesla | Q34067236 | ||
| 7-T MR--from research to clinical applications? | Q34079073 | ||
| Magnetic resonance imaging based clinical research in Alzheimer's disease | Q34123178 | ||
| Statin users without an APOE-epsilon4 allele have increased insulin resistance | Q34155597 | ||
| Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study | Q34247831 | ||
| 2012 Alzheimer's disease facts and figures | Q34260109 | ||
| Review: taurine: a "very essential" amino acid. | Q34312980 | ||
| Regional myo-inositol concentration in mild cognitive impairment Using 1H magnetic resonance spectroscopic imaging | Q34576451 | ||
| Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. | Q34652032 | ||
| Association of 1H-MR spectroscopy and cerebrospinal fluid biomarkers in Alzheimer's disease: diverging behavior at three different brain regions | Q34665673 | ||
| Reduced hippocampal glutamate in Alzheimer disease | Q34985347 | ||
| Noninvasive quantification of ascorbate and glutathione concentration in the elderly human brain | Q35056484 | ||
| Brain metabolic correlates of decision making in amnestic mild cognitive impairment | Q35097548 | ||
| Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults | Q35210272 | ||
| Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia: a prospective cohort study | Q35319467 | ||
| Scyllo-inositol in normal aging human brain: 1H magnetic resonance spectroscopy study at 4 Tesla | Q35677156 | ||
| Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging | Q35677174 | ||
| The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging | Q35758628 | ||
| Comparison of single-shot localization methods (STEAM and PRESS) for in vivo proton NMR spectroscopy | Q35792156 | ||
| In vivo magnetic resonance spectroscopy of GABA: a methodological review | Q36060201 | ||
| Evidence for ordering of Alzheimer disease biomarkers | Q36071403 | ||
| Proton MR spectroscopy-detectable major neurotransmitters of the brain: biology and possible clinical applications | Q36232627 | ||
| Combining structural brain changes improves the prediction of Alzheimer's disease and mild cognitive impairment | Q36374662 | ||
| Spatial localization in NMR spectroscopy in vivo | Q36448283 | ||
| Temporal dynamics of lactate concentration in the human brain during acute inspiratory hypoxia | Q36626001 | ||
| Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment | Q36789901 | ||
| Clinical applications of proton MR spectroscopy | Q36815275 | ||
| Observation of resolved glucose signals in 1H NMR spectra of the human brain at 4 Tesla | Q36818274 | ||
| Magnetic resonance spectroscopy (MRS) in the evaluation of pediatric brain tumors, Part I: Introduction to MRS. | Q36832435 | ||
| Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia | Q37010486 | ||
| Single voxel magnetic resonance spectroscopy at 3 Tesla in a memory disorders clinic: early right hippocampal NAA/Cr loss in mildly impaired subjects | Q37097465 | ||
| 1H magnetic resonance spectroscopy in dementia | Q37150637 | ||
| MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia | Q37150803 | ||
| Measurement sequences for single voxel proton MR spectroscopy. | Q37206676 | ||
| White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI. | Q37319527 | ||
| Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes | Q37345411 | ||
| Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study | Q37407266 | ||
| Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study | Q37462401 | ||
| Neuroimaging results impose new views on Alzheimer's disease--the role of amyloid revised | Q37971458 | ||
| Longitudinal metabolic and cognitive changes in mild cognitive impairment patients | Q38389274 | ||
| Metabolite investigation in both anterior and posterior cingulate gyri in Alzheimer's disease spectrum using 3-tesla MR spectroscopy | Q38461379 | ||
| Functional investigation of bilateral posterior cingulate gyri using multivoxel MR spectroscopy | Q38463897 | ||
| Magnetic resonance characterization of ischemic tissue metabolism | Q39979430 | ||
| Taurine is a potent activator of extrasynaptic GABA(A) receptors in the thalamus. | Q40028844 | ||
| Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease | Q40243026 | ||
| Utilization of glutamine and of TCA cycle constituents as precursors for transmitter glutamate and GABA. | Q40559826 | ||
| In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging | Q41614051 | ||
| An Open-Label Exploratory Study with Memantine: Correlation between Proton Magnetic Resonance Spectroscopy and Cognition in Patients with Mild to Moderate Alzheimer's Disease | Q42103589 | ||
| P275 | copyright license | Creative Commons Attribution 2.5 Generic | Q18810333 |
| P433 | issue | 4 | |
| P921 | main subject | proton NMR | Q1979695 |
| brain | Q1073 | ||
| nervous system | Q9404 | ||
| Alzheimer's disease | Q11081 | ||
| biomedical investigative technique | Q66648976 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 367-388 | |
| P577 | publication date | 2014-05-01 | |
| P1433 | published in | Current Alzheimer Research | Q5195031 |
| P1476 | title | Advances in high-field magnetic resonance spectroscopy in Alzheimer's disease | |
| P478 | volume | 11 |
| Q89122013 | 1H MRS spectroscopy in preclinical autosomal dominant Alzheimer disease |
| Q55031002 | Acupuncture therapy in treating migraine: results of a magnetic resonance spectroscopy imaging study. |
| Q30910766 | Anatomical, functional and molecular biomarker applications of magnetic resonance neuroimaging |
| Q90049842 | Brain Amide Proton Transfer Imaging of Rat With Alzheimer's Disease Using Saturation With Frequency Alternating RF Irradiation Method |
| Q33701135 | Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images |
| Q92463658 | European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND) |
| Q92671500 | Functional MRI technologies in the study of medication treatment effect on Alzheimer's disease |
| Q35276630 | HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease? |
| Q37430416 | Human Neural Stem Cell Transplantation Rescues Cognitive Defects in APP/PS1 Model of Alzheimer's Disease by Enhancing Neuronal Connectivity and Metabolic Activity |
| Q35857773 | Neurometabolic characteristics in the anterior cingulate gyrus of Alzheimer's disease patients with depression: a (1)H magnetic resonance spectroscopy study |
| Q36177915 | Quantitative in vivo neurochemical profiling in humans: where are we now? |
| Q51761581 | Royal Jelly Reduces Cholesterol Levels, Ameliorates Aβ Pathology and Enhances Neuronal Metabolic Activities in a Rabbit Model of Alzheimer's Disease. |
Search more.